Background: Relative survival, a methodology previously used in epidemiologic studies of cancer, compares the observed survival of a patient cohort with expected survival derived from general population life tables. We examined relative survival in patients treated by long-term dialysis in the Italian Dialysis and Transplantation Registry in order to determine the prognosis of dialysis patients.
M
ortality in dialysis registries usually is defined by cause-specific or all-cause mortality. 1, 2 With the first method, deaths are attributed to a specific disease, while all other causes are censored. In contrast, all-cause (or crude) mortality includes all deaths within the cohort being studied without distinguishing those caused by the disease of interest from those arising from other factors. The main limitation of cause-specific mortality is that it provides useful information only if the registered causes of death are reliable; this usually is not the case for dialysis registries or, in general, observational studies. 3 However, all-cause survival analysis is limited by the failure to discriminate between deaths due to the disease of interest and deaths due to other causes. In general, these approaches are not very useful for estimating prognosis in renal replacement therapy patients due to lack of comparisons with the general population. Chronic kidney disease rarely is considered a cause of death; rather, it commonly is perceived as a factor that enhances the effect of other causes, 4 such as heart diseases and infections. Thus, it is difficult to determine the prognosis of patients treated by long-term dialysis.
In cancer registries, this problem was solved by analyzing relative survival instead of cause-specific or crude survival. This methodology matches the survival of patients with a specific malignancy with that of a standard reference population (usually life tables of a national or regional population). The relative survival method relies on the assumption that the prevalence of the disease is low and has little impact on overall estimates. Chronic kidney disease fulfills this assumption because it has negligible impact on all-cause mortality in the general population. If we compare the mortality of a cohort of dialysis patients with that of a matched cohort extracted from the general population, the only factor that distinguishes these individuals is dialysis therapy; thus, any mortality excess observed may be safely attributed to this factor.
We used the relative survival method to estimate the decrease in survival directly due to dialysis therapy in patients of the Italian Dialysis and Transplantation Registry (IDTR) in order to estimate their prognosis. Moreover, we tried to identify special subgroups of patients at high risk of death in order to uncover which patients should be the focus of research aimed at ameliorating prognosis.
METHODS
Our analysis is based on data from the IDTR. We performed a cohort study by selecting all patients starting hemodialysis or peritoneal dialysis therapy from January 1, 2000, to December 31, 2008, in Italy. Changes in treatment modality or death were registered until December 31, 2008. Only patients coming from Italian regions able to provide complete follow-up information were enrolled, no other eligibility criteria were applied.
Data were collected in accordance with Italian law; the IDTR is an anonymous collection of regional registries, instituted by regional laws. Informed consent is requested from patients starting dialysis therapy to allow for data collection within the framework of the registries and provision of these data to the IDTR in an anonymous form.
Data considered in this study were date of first treatment, sex, age (divided into 5 classes: Ͻ25, 25-45, 45-65, 65-75, and Ն75 years), primary kidney disease (grouped into congenital and hereditary disease, diabetes, primary glomerulonephritis, pyelonephritis, systemic diseases, vascular, unknown, and others), prevailing dialysis modality (hemodialysis and peritoneal dialysis), kidney transplant, main comorbid conditions (heart disease, heart failure, cerebral vascular disease, peripheral vascular disease, diabetes, chronic lung disease, cancer, and hypertension) defined according to, 5 death, and date of death. The outcome was death from any cause.
For each patient, survival was calculated from the first dialysis treatment to death or to December 31, 2008, if alive at the end of follow-up. If the patient shifted from peritoneal dialysis to hemodialysis therapy or vice versa, he or she was assigned to the longer-lasting treatment. Successful kidney transplant recipients and lost patients were censored at the date of the last scheduled dialysis session.
Information bias could occur for incomplete reporting of the outcome, leading to overestimation of survival. Therefore, we compared mortality rates among Italian regions, but did not find significant differences. The kidney transplant rate was similar to the value provided by the National Transplantation Center. The number of patients lost to follow-up was negligible.
The number of cases in the Italian regions with complete follow-up in the study period determined sample size.
Relative survival (the ratio of observed survival in the group of interest to expected survival based on the age-and period-specific mortality of the general population from which the group was derived 6 ) can be calculated from the life table of the general population. In this case, the study sample comprised IDTR participants who began dialysis therapy in 2000-2008 and the reference population was the total Italian population of the same age and sex. The basic assumption is that the expected mortality experienced by the study sample during a particular period would be the same as mortality in the general population.
First, the population (l) at the start of each interval in each yearly cohort and the number of deaths (d) and those lost to follow-up (w) during the interval were determined. The population at risk (l= ϭ l -(w/2)) and interval-specific survival (p ϭ 1 -[d/l=]) were estimated by assuming withdrawals and deaths were distributed evenly over the interval.
Cumulative survival (CP) for a particular interval (i) then was obtained by the cumulative product of the interval-specific survival, where the initial cumulative survival (CP[0]) was equal to 1 and
Expected survival probabilities (p*) were obtained from Italian population life tables 7 by multiplication of the published annual probabilities of survival. The appropriate probability, depending on the sex and age of the patient and year of registration, was obtained. The probabilities of each follow-up interval were multiplied to obtain the expected cumulative survival (CP*).
As a last step, interval-specific and cumulative relative survival ratios (R and CR) were calculated as the ratios of the observed and expected interval-specific and cumulative survivals: R ϭ p/p* and CR ϭCP/CP*.
Excess mortality rate (EMR) could be obtained easily from the difference between observed (d) and expected deaths (d*) (also obtained from the Italian life table) divided by person-time at risk (y) in each interval (i):
Relative survival and the excess mortality rate are estimated here according to the Ederer II method, 8 in which matched individuals are treated as being at risk until the corresponding patient dies or is censored.
In the relative survival model, piecewise constant hazards are assumed. This treats the number of deaths in each interval as a Poisson process. In this way, by using a Poisson assumption for the observed number of deaths, the model may be estimated in the framework of generalized linear models. 9 The exponentiated coefficient estimates of the Poisson model give estimations of the ratios between observed and expected deaths and thus may be interpreted as excess hazard ratios, also known as relative excess risks. This comparative measure is based solely on the component of risk due to the exposures because it removes the background risk. 10 Goodness of fit was assessed using the deviance Pearson 2 statistics. Statistical analysis was performed using Stata, version 11 (StataCorp, www.stata.com).
RESULTS
The IDTR is a collection of 17 regional registries. In January 2000 to December 2008, a total of 45,427 individuals started either hemodialysis or peritoneal dialysis therapy. Because only 8 of the 17 regions were able to provide complete follow-up data, only the 27,642 patients belonging to these regions were considered. They constituted 61% of the full data set. The percentage of coverage in these 8 regions was 91%. Five-year observed and expected survivals were 47.4% and 85.0%, respectively, yielding a relative survival estimate of 55.6% (95% CI, 54.7%-56.5%). In other words, survival was less than expected for the general population by 44.4% (Table 2 ; Fig 1) . Fiveyear relative survival was 56.8% (95% CI, 55.6%-57.9%) in men and 53.5% (95% CI, 52.1%-55.0%) in women. As listed in Table 3 , relative survival largely differed according to age category, being particularly low in the 2 oldest groups. Five-year relative survival was 55% (95% CI, 54%-56%) in hemodialysis patients and 58% (95% CI, 56%-60%) in peritoneal dialysis patients.
The excess mortality rate did not stay constant over the time elapsed since dialysis therapy start. As shown in Table 2 and Fig 2, the excess mortality rate peaks at 21 deaths/100 patient-years at 3 months, decreases to 16 deaths/100 patient-years at 6 months, then reaches a plateau after 1 year, remaining relatively constant at around 10 deaths/100 patient-years until year 8. The decrease in excess mortality rate was similar for men and women (Fig 3) , suggesting that the first-year excess of deaths is independent of sex.
In Fig 4 , mortality rate excess by age category is shown. It remains relatively stable over time in patients younger than 65 years, but decreases in the first 6 months in patients older than 65 years. Note: Expected survival corresponds to survival drawn from the general population. Expected mortality is the mortality of a subset of individuals in the general population comparable to dialysis patients.
Abbreviation: py, person-year. a When provided, 95% confidence intervals are shown in parentheses. The excess mortality rate stratified by primary kidney disease is shown in Fig 5. The increase in excess mortality in the earliest period after starting dialysis therapy was observed in mainly 2 diagnostic categories: systemic disease and miscellaneous categories. In the systemic disease category, 39% of patients had multiple myeloma, and in the miscellaneous category, 33% of patients had kidney neoplasms; thus, many early deaths occur in patients affected by cancer.
The excess mortality time trend differed, showing an initial peak with a rapid decrease in hemodialysis and a modest progressive increase in peritoneal dialysis (Fig 6) .
Excess mortality was modeled using Poisson regression in order to examine the possible determinants of excess hazard ratios, also known as relative excess risks. Table 4 lists unadjusted and adjusted relative excess risks. Patients who survived the first year had lower relative excess risk. Older age, systemic diseases, and diabetes had the strongest association with excess mortality. As listed in Table 5 , which reports the interaction between follow-up period and type of dialysis, peritoneal dialysis was associated with lower relative excess risk in only the first year of treatment, but since the second year, relative excess risk was higher than in hemodialysis. The assessed goodness of fit did not show evidence of lack of fit.
DISCUSSION
Relative survival is the standard measure of survival in cancer registries 11, 12 and has been proposed for use in other chronic diseases, such as cardiovascular disease 13 and diabetes. 14 Relative survival may be understood as the survival of a population affected by a particular disease under study, adjusted for all other competing causes of death. Dialysis patients, as part of the general population, are not isolated from the lifestyle risks and environmental and infectious determinants of diseases affecting the community as a whole. The possible risk factors relevant for dialysis patients may be split into 2 components: the background mortality typical of the population plus the excess due to dialysis. Some parallels exist between dialysis patients and patients with cancer: both are affected by chronic diseases, both have extended survival data collected about them, and for each of these 2 groups, there are annual registries that make such data available. This similarity encouraged us to broaden the use of relative survival methodology to the field of renal replacement therapy.
By using this methodology, we were able to estimate the prognosis of dialysis patients receiving longterm dialysis, showing that they experience survival of 55% at 5 years in comparison to the general population. To our knowledge, this is the first time that dialysis patients' prognosis has been measured by determining its relationship to background survival.
This method offers additional advantages because relative survival makes dialysis patients' outcomes comparable between different countries and health care systems and between different chronic diseases, allowing adjustment for the background mortality of the source population. 15 For example, the US Renal Data System (USRDS) reports a higher mortality rate than European or Japanese registries, a difference that might be due at least in part to the respective source population: Japan has the highest life expectancy in the world, and almost all Western European countries have a higher life expectancy than the United States. 16 The 5-year relative survival of dialysis patients is lower than that reported for regional breast cancer (84%), regional colon cancer (69.5%), and regional kidney cancer (62.7%), but higher than that for chronic heart failure (35%) and regional lung cancer (24%).
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It is possible to rank the severity of different chronic diseases and compare their prognosis (Fig 7) . From this perspective, dialysis patients need at least as much attention as cancer patients from health authorities and public opinion.
An interesting characteristic shown by the relative survival of dialysis patients is the absence of leveling off over time. This implies that individuals receiving dialysis are never cured (at least in a statistical sense) because it is inevitable that they will die earlier than matched individuals in the general population. Contrary to what happens in neoplastic diseases, for which a proportion of patients are cured, dialysis patients never heal and thus no cure model may be proposed.
When modeling relative survival, we try to estimate directly the excess mortality experienced by patients receiving dialysis compared with that of the general population, thereby obtaining an estimate of net survival. In the first year of dialysis therapy, mortality is exceedingly high, identifying a subgroup of patients who do not benefit from it. These patients make up about 15% of the observed population. That dialysis patients undergo early high mortality during renal replacement therapy has been reported previously, [18] [19] [20] [21] but its description as mortality rate excess provides a more accurate measure because it is independent of the incidence of the disease. In many dialysis registries, the early mortality excess emerges only partially because these registries exclude the first 3 months of renal replacement therapy. 1 It is estimated that patients not registered in the USRDS in the first 3 months are about 6% of the incident population. 19 After the first year, there is a decrease in risk of excess mortality, an observation that is preserved even after adjustment for age, primary kidney disease, and comorbid conditions.
Early excess mortality has been reported in patients undergoing hemodialysis treatment only, likely due to selection bias because the most severely affected patients are not accepted into a peritoneal dialysis program. 22 However, evidence is lacking that peritoneal dialysis is unsuitable for the sickest patients. Although (accounting for background mortality) relative excess risk is lower in the first year of peritoneal dialysis compared with hemodialysis therapy, it becomes at least twice that of hemodialysis from the second year onward. Thus, our comparison shows results similar to the CHOICE (Choices for Healthy Outcomes in Caring for ESRD) Study 23 ; namely, an initial advantage survival given by peritoneal dialysis in the first year, followed by the hemodialysis advantage survival up to the seventh year. However, this result must be interpreted very cautiously because the censoring due to kidney transplant may not be uninformative, as required in survival analysis. Because about 15% of peritoneal dialysis patients underwent transplant versus only 9% of hemodialysis patients, the mortality of peritoneal dialysis patients could have been overestimated. 24 The impact of age on excess mortality risk is very relevant. Having taken into account that this measure is already adjusted for background mortality due to age itself, we showed that the relative excess risk of older patients is much higher. This means that the outcome of dialysis patients is more severe in fragile individuals.
Modeling of the excess mortality rate confirms results of the univariate analysis: the strongest predictors of excess mortality were age and some primary kidney diseases. The other covariates, such as sex and comorbid conditions, even if statistically significant, have only a marginal effect. It is worth emphasizing that women have a higher risk of death than men if background mortality is considered. This is another example of reverse epidemiology that may be found in dialysis patients.
There are 3 major limitations to this study. First, the cohort of patients available for our analysis makes up only about half the Italian patients who began receiving dialysis in the selected period. However, this pitfall is minimized by our taking into consideration only the Italian regions able to provide full data sets. Mortality rates were very similar and consistent within regions; thus, results probably are generalizable to the entire nation. Second, at least 2 regions had coverage less than 70% and one of them contributed substantially to the number of patients, thus possibly biasing results in an indeterminate way. However, a previous analysis performed on a single region with coverage near 100% gave similar results (Nordio M, Antonucci F, unpublished data), suggesting that the bias, if present, should not be critical. Third, although the relative survival method allows us to override the competing risks derived from different causes of death that compete each other, it cannot treat competing risks arising from changes in renal replacement modality; for example, death on dialysis therapy prevented by kidney transplant.
In conclusion, this study emphasizes the usefulness of relative survival methodology in dialysis patients. This measure allows estimation of the prognosis of the disease and comparison of its severity with other chronic diseases. It provides a useful tool for comparing outcomes between dialysis registries because it takes into account the characteristics of the source population. The excess mortality rate seems a suitable measure to describe the trend of mortality in dialysis populations in a much more sensitive and informative way than that provided by the simple assessment of proportion of survivors. Because to our knowledge this is the first study that uses these measures in a dialysis registry, the worth of the methodology cannot be validated fully, but we hope that further studies will exploit its potential.
